Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
153 hedge funds and large institutions have $363M invested in Progenics Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 16 closing their positions.
69% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 16
8% more funds holding
Funds holding: 142 → 153 (+11)
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
17% less capital invested
Capital invested by funds: $439M → $363M (-$75.7M)
42% less call options, than puts
Call options by funds: $1.37M | Put options by funds: $2.37M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.23M |
| 2 |
State Street
Boston,
Massachusetts
|
+$818K |
| 3 |
New York State Teachers Retirement System (NYSTRS)
Albany,
New York
|
+$632K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$622K |
| 5 |
JP Morgan Chase
New York
|
+$538K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.6M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.61M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.83M |
PGNX Hedge Fund Activity: Q4 2017 in Review
153 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2017, worth a combined $363M — down 17% from $439M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PGNX positions and 16 closed out — a net gain of 11 holders — while 48 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $1.23M. The largest seller was Fidelity Investments, cutting an estimated $3.6M.
- 153 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2017, up from 142 in Q3 2017.
- Funds reported $363M of Progenics Pharmaceuticals Inc stock for Q4 2017, down 17% quarter-over-quarter.
- 27 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2017 and 16 closed out, a net change of +11 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2017 was BlackRock, an estimated $1.23M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2017 was Fidelity Investments, an estimated $3.6M sold.
Based on aggregated 13F filings for Q4 2017.